A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Br J Cancer
; 129(6): 965-973, 2023 10.
Article
in En
| MEDLINE
| ID: mdl-37537253
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms, Castration-Resistant
Type of study:
Clinical_trials
Limits:
Humans
/
Male
Language:
En
Journal:
Br J Cancer
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: